Who Buys Imipenem from India — 302 Importers Behind a $33.3M Market

The importation of Imipenem from India involves various buyer segments, each with distinct purchasing behaviors:

• Distributors: Entities like Yusen Logistics Benelux Belgium (Belgium, $2.21M) and Pharmedic SA (Ecuador, $1.29M) function as intermediaries, procuring large quantities to supply regional markets. Their purchasing patterns are characterized by bulk orders to meet the demands of multiple clients.

• Hospital Groups: Organizations such as M/S. Sun Pharmaceuticals Morocco LL (Morocco, $1.41M) and Bank of Ceylon (Sri Lanka, $1.17M) represent healthcare institutions acquiring Imipenem for direct patient care. Their procurement is typically based on anticipated patient needs and treatment protocols, leading to regular, sizable orders.

• Government Procurement Agencies: Entities like Bank of Ceylon (Sri Lanka, $1.17M) often engage in tender-based purchasing to supply public healthcare facilities. Their buying behavior is influenced by national health policies and budget allocations, resulting in periodic, large-scale procurements.

• Re-exporters: Companies such as Yusen Logistics Benelux Belgium Keetberglaan (Belgium, $0.83M) may purchase Imipenem for redistribution to other markets. Their order patterns are driven by global demand fluctuations and trade agreements, leading to variable purchasing volumes.

• Contract Manufacturers: Firms like L J S.A de CV (Mexico, $1.09M) and L J S A D C (Mexico, $0.94M) might procure Imipenem as an active pharmaceutical ingredient for formulation into finished products. Their procurement is aligned with production schedules and client contracts, resulting in consistent, moderate-sized orders.

Mexico:

1. 1Regulatory Authority: Comisión Federal para la Protección contra Riesgos Sanitarios (COFEPRIS).
2. 2Import Registration Process: Importers must obtain a Sanitary Registration, involving submission of product dossiers, quality control documentation, and compliance with Good Manufacturing Practices (GMP).
3. 3Estimated Timeline: Approximately 6-12 months, depending on dossier completeness and regulatory workload.
4. 4Import Tariff/Duty: For HS Code 30049099, the import duty is typically 0%, but importers should verify current rates with Mexican customs authorities.

Belgium:

1. 1Regulatory Authority: Federal Agency for Medicines and Health Products (FAMHP).
2. 2Import Registration Process: Requires a Marketing Authorization (MA), necessitating submission of a Common Technical Document (CTD), including clinical data and GMP certification.
3. 3Estimated Timeline: Approximately 7-12 months, subject to the evaluation process and any additional information requests.
4. 4Import Tariff/Duty: As an EU member, Belgium applies a 0% import duty on pharmaceutical products under HS Code 30049099.

Sri Lanka:

1. 1Regulatory Authority: National Medicines Regulatory Authority (NMRA).
2. 2Import Registration Process: Involves obtaining a Registration Certificate by submitting product dossiers, including quality, safety, and efficacy data, along with GMP compliance.
3. 3Estimated Timeline: Approximately 6-9 months, depending on the review process and any required clarifications.
4. 4Import Tariff/Duty: Import duties for HS Code 30049099 are generally low, often around 0-5%, but importers should confirm current rates with Sri Lankan customs.

Morocco:

1. 1Regulatory Authority: Direction du Médicament et de la Pharmacie (DMP).
2. 2Import Registration Process: Requires a Marketing Authorization, involving submission of a comprehensive dossier detailing product quality, safety, efficacy, and GMP certification.
3. 3Estimated Timeline: Approximately 8-12 months, subject to the completeness of the application and regulatory review.
4. 4Import Tariff/Duty: Pharmaceutical products under HS Code 30049099 typically attract an import duty of around 2.5%, but rates should be verified with Moroccan customs authorities.

Myanmar:

1. 1Regulatory Authority: Food and Drug Administration (FDA) Myanmar.
2. 2Import Registration Process: Importers must obtain a Product Registration Certificate by submitting detailed dossiers, including quality control data, clinical studies, and GMP compliance.
3. 3Estimated Timeline: Approximately 9-12 months, depending on the thoroughness of the submission and regulatory workload.
4. 4Import Tariff/Duty: Import duties for HS Code 30049099 are generally low, often around 0-5%, but importers should confirm current rates with Myanmar customs.

The demand for Imipenem in importing countries is driven by several factors:

• Disease Prevalence: Imipenem is a broad-spectrum antibiotic used to treat severe bacterial infections, including those caused by multidrug-resistant organisms. The rising incidence of such infections globally has increased the need for effective treatments.

• Government Healthcare Programs: Many countries have implemented programs to combat antimicrobial resistance, leading to increased procurement of antibiotics like Imipenem. For instance, national action plans focusing on antimicrobial stewardship have been established in various regions.

• Universal Health Coverage Expansion: Efforts to achieve universal health coverage have led to improved access to essential medicines. Countries expanding their healthcare infrastructure and coverage are likely to increase imports of critical antibiotics.

• WHO Essential Medicines List Procurement: Imipenem is included in the WHO Model List of Essential Medicines, guiding countries in prioritizing procurement to ensure availability in public health systems.

• Tender-Based Purchasing: Many governments and large healthcare providers utilize tender systems to procure medicines, ensuring cost-effectiveness and consistent supply. This approach often results in bulk purchasing of essential antibiotics like Imipenem.

With 302 buyers across 94 countries, the global market for Imipenem presents significant opportunities. The combination of increasing antimicrobial resistance, governmental health initiatives, and structured procurement processes underscores the sustained demand for this antibiotic.

The importation of Imipenem from India involves various buyer segments, each with distinct purchasing behaviors:

• Distributors: Entities like Yusen Logistics Benelux Belgium (Belgium, $2.21M) and Pharmedic SA (Ecuador, $1.29M) function as intermediaries, procuring large quantities to supply regional markets. Their purchasing patterns are characterized by bulk orders to meet the demands of multiple clients.

• Hospital Groups: Organizations such as M/S. Sun Pharmaceuticals Morocco LL (Morocco, $1.41M) and Bank of Ceylon (Sri Lanka, $1.17M) represent healthcare institutions acquiring Imipenem for direct patient care. Their procurement is typically based on anticipated patient needs and treatment protocols, leading to regular, sizable orders.

• Government Procurement Agencies: Entities like Bank of Ceylon (Sri Lanka, $1.17M) often engage in tender-based purchasing to supply public healthcare facilities. Their buying behavior is influenced by national health policies and budget allocations, resulting in periodic, large-scale procurements.

• Re-exporters: Companies such as Yusen Logistics Benelux Belgium Keetberglaan (Belgium, $0.83M) may purchase Imipenem for redistribution to other markets. Their order patterns are driven by global demand fluctuations and trade agreements, leading to variable purchasing volumes.

• Contract Manufacturers: Firms like L J S.A de CV (Mexico, $1.09M) and L J S A D C (Mexico, $0.94M) might procure Imipenem as an active pharmaceutical ingredient for formulation into finished products. Their procurement is aligned with production schedules and client contracts, resulting in consistent, moderate-sized orders.

Mexico:

1. 1Regulatory Authority: Comisión Federal para la Protección contra Riesgos Sanitarios (COFEPRIS).
2. 2Import Registration Process: Importers must obtain a Sanitary Registration, involving submission of product dossiers, quality control documentation, and compliance with Good Manufacturing Practices (GMP).
3. 3Estimated Timeline: Approximately 6-12 months, depending on dossier completeness and regulatory workload.
4. 4Import Tariff/Duty: For HS Code 30049099, the import duty is typically 0%, but importers should verify current rates with Mexican customs authorities.

Belgium:

1. 1Regulatory Authority: Federal Agency for Medicines and Health Products (FAMHP).
2. 2Import Registration Process: Requires a Marketing Authorization (MA), necessitating submission of a Common Technical Document (CTD), including clinical data and GMP certification.
3. 3Estimated Timeline: Approximately 7-12 months, subject to the evaluation process and any additional information requests.
4. 4Import Tariff/Duty: As an EU member, Belgium applies a 0% import duty on pharmaceutical products under HS Code 30049099.

Sri Lanka:

1. 1Regulatory Authority: National Medicines Regulatory Authority (NMRA).
2. 2Import Registration Process: Involves obtaining a Registration Certificate by submitting product dossiers, including quality, safety, and efficacy data, along with GMP compliance.
3. 3Estimated Timeline: Approximately 6-9 months, depending on the review process and any required clarifications.
4. 4Import Tariff/Duty: Import duties for HS Code 30049099 are generally low, often around 0-5%, but importers should confirm current rates with Sri Lankan customs.

Morocco:

1. 1Regulatory Authority: Direction du Médicament et de la Pharmacie (DMP).
2. 2Import Registration Process: Requires a Marketing Authorization, involving submission of a comprehensive dossier detailing product quality, safety, efficacy, and GMP certification.
3. 3Estimated Timeline: Approximately 8-12 months, subject to the completeness of the application and regulatory review.
4. 4Import Tariff/Duty: Pharmaceutical products under HS Code 30049099 typically attract an import duty of around 2.5%, but rates should be verified with Moroccan customs authorities.

Myanmar:

1. 1Regulatory Authority: Food and Drug Administration (FDA) Myanmar.
2. 2Import Registration Process: Importers must obtain a Product Registration Certificate by submitting detailed dossiers, including quality control data, clinical studies, and GMP compliance.
3. 3Estimated Timeline: Approximately 9-12 months, depending on the thoroughness of the submission and regulatory workload.
4. 4Import Tariff/Duty: Import duties for HS Code 30049099 are generally low, often around 0-5%, but importers should confirm current rates with Myanmar customs.

The demand for Imipenem in importing countries is driven by several factors:

• Disease Prevalence: Imipenem is a broad-spectrum antibiotic used to treat severe bacterial infections, including those caused by multidrug-resistant organisms. The rising incidence of such infections globally has increased the need for effective treatments.

• Government Healthcare Programs: Many countries have implemented programs to combat antimicrobial resistance, leading to increased procurement of antibiotics like Imipenem. For instance, national action plans focusing on antimicrobial stewardship have been established in various regions.

• Universal Health Coverage Expansion: Efforts to achieve universal health coverage have led to improved access to essential medicines. Countries expanding their healthcare infrastructure and coverage are likely to increase imports of critical antibiotics.

• WHO Essential Medicines List Procurement: Imipenem is included in the WHO Model List of Essential Medicines, guiding countries in prioritizing procurement to ensure availability in public health systems.

• Tender-Based Purchasing: Many governments and large healthcare providers utilize tender systems to procure medicines, ensuring cost-effectiveness and consistent supply. This approach often results in bulk purchasing of essential antibiotics like Imipenem.

With 302 buyers across 94 countries, the global market for Imipenem presents significant opportunities. The combination of increasing antimicrobial resistance, governmental health initiatives, and structured procurement processes underscores the sustained demand for this antibiotic.